View Older Stories View More Recent Stories

Jul 24, 2020 01:26PM Gilead Sciences (GILD) Kite Announced FDA Accelerated Approval of Tecartus to Treat MCL
Jul 24, 2020 01:25PM U.S. FDA Approves Kite’s Tecartus™, the First and Only CAR T Treatment for Relapsed or Refractory Mantle Cell Lymphoma
Jul 16, 2020 04:01PM Gilead Sciences to Release Second Quarter 2020 Financial Results on Thursday, July 30, 2020
Jul 10, 2020 08:31AM Gilead Sciences (GILD) Presents Additional Data on Remdesivir for Treatment of COVID-19
Jul 10, 2020 08:30AM Gilead Presents Additional Data on Investigational Antiviral Remdesivir for the Treatment of COVID-19
Jul 8, 2020 04:01AM Gilead Sciences Presents Survey Findings on PrEP Access and Utilization in the U.S. During COVID-19 Shelter-in-Place Orders
Jul 4, 2020 03:01AM New Findings on Gilead’s Biktarvy® Presented at AIDS 2020: Virtual Include Positive Switch Data in Older Adults
Jul 4, 2020 03:01AM Gilead Sciences Presents Data Supporting a Potential Six-Month Dosing Interval for Investigational HIV-1 Capsid Inhibitor Lenacapavir (GS-6207)
Jul 3, 2020 07:56AM European Commission Grants Conditional Marketing Authorization for Gilead’s Veklury® (remdesivir) for the Treatment of COVID-19
Jul 1, 2020 08:30AM Gilead Sciences Demonstrates Commitment to Scientific Innovation In HIV With New Prevention, Treatment and Cure Research Data Presented At AIDS 2020: Virtual
Jun 12, 2020 08:03AM Gilead Sciences (GILD) Company, Kite, Granted European Medicines Agency Approval for CAR T Cell Therapy Manufacturing Facility in Europe
Jun 12, 2020 08:00AM Kite Receives European Medicines Agency Approval for CAR T Cell Therapy Manufacturing Facility in Europe
Jun 4, 2020 01:10PM Chinese and Iranian hackers targeted Biden and Trump campaigns, Google says
Jun 1, 2020 04:05PM Mark Genovese Joins Gilead to Lead Clinical Development of Company’s Inflammation Programs
Jun 1, 2020 08:33AM Gilead Sciences (GILD) Remdesivir Moderate COVID-19 Study Shows 65% More Likely to have Clinical Improvement at Day 11
Jun 1, 2020 08:30AM Gilead Announces Results From Phase 3 Trial of Remdesivir in Patients With Moderate COVID-19
May 29, 2020 08:02AM Gilead Sciences (GILD) Announces Yescarta Demonstrates High Rates of Response in Relapsed or Refractory Indolent Non-Hodgkin Lymphoma
May 29, 2020 08:02AM Gilead Sciences (GILD) Announces Investigational Magrolimab in Combination With Azacitidine Demonstrates Durable Activity in Previously-Untreated Myelodysplastic Syndrome and AML
May 29, 2020 08:00AM Investigational Magrolimab in Combination With Azacitidine Demonstrates Durable Activity in Previously-Untreated Myelodysplastic Syndrome and Acute Myeloid Leukemia
May 29, 2020 08:00AM Yescarta® (Axicabtagene Ciloleucel) Demonstrates High Rates of Response in Relapsed or Refractory Indolent Non-Hodgkin Lymphoma
May 13, 2020 05:00PM Gilead and Kite Continue to Advance Next Generation Cancer Therapies at 2020 American Society of Clinical Oncology Annual Meeting
May 7, 2020 11:47AM Gilead Sciences (GILD) Confirms Approval of Remdesivir in Japan for Patients With Severe COVID-19
May 7, 2020 11:45AM Gilead Announces Approval of Veklury® (remdesivir) in Japan for Patients With Severe COVID-19
May 1, 2020 04:23PM Gilead (GILD) sets goal of producing at least 500,000 treatment courses of remdesivir by October
May 1, 2020 04:19PM Gilead’s Investigational Antiviral Remdesivir Receives U.S. Food and Drug Administration Emergency Use Authorization for the Treatment of COVID-19
Apr 30, 2020 04:02PM Gilead Sciences Announces Second Quarter 2020 Dividend
Apr 29, 2020 08:38AM Gilead Sciences (GILD) Phase 3 Trial of Remdesivir in Severe COVID-19 Patients Shows Improvement
Apr 29, 2020 08:35AM Gilead Announces Results From Phase 3 Trial of Investigational Antiviral Remdesivir in Patients With Severe COVID-19
Apr 16, 2020 05:30PM Gilead Sciences to Release First Quarter 2020 Financial Results on Thursday, April 30, 2020
Apr 15, 2020 04:15PM Gilead Provides Additional Information Regarding 2020 Annual Meeting of Stockholders Due to COVID-19 Precautions
Apr 11, 2020 10:48AM Gilead Sciences (GILD) Remdesivir Study Shows Two-Third of Severe COVID-19 Patients Improved
Apr 10, 2020 03:31PM Data on 53 Patients Treated With Investigational Antiviral Remdesivir Through the Compassionate Use Program Published in New England Journal of Medicine
Apr 8, 2020 01:09PM Gilead Announces $20 Million Philanthropic Fund to Support Nonprofit Organizations Impacted by the COVID-19 Crisis
Apr 7, 2020 08:32AM Gilead Sciences (GILD) Completes Forty Seven (FTSV) Acquisition
Apr 7, 2020 08:32AM Gilead Completes Acquisition of Forty Seven, Inc.
Mar 30, 2020 08:31AM Gilead Sciences (GILD) Announces Expiration of Hart-Scott-Rodino Waiting Period for Forty Seven Tender Offer
Mar 30, 2020 08:30AM Gilead Announces Expiration of Hart-Scott-Rodino Waiting Period for Forty Seven Tender Offer
Mar 19, 2020 02:41PM Gilead (GILD) Announces FDA Approval for Epclusa for Children Ages 6 and Older with HCV
Mar 19, 2020 02:40PM U.S. Food And Drug Administration Approves Epclusa® (Sofosbuvir/Velpatasvir) for Children Ages 6 and Older or Weighing at Least 17 kg with Chronic Hepatitis C Infection
Mar 11, 2020 03:12PM Gilead Sciences (GILD) Announces New Clinical Study Data for its Investigational HIV-1 Capsid Inhibitor GS-6207 Presented at CROI 2020
Mar 11, 2020 03:09PM New Clinical Study Data for Gilead’s Investigational HIV-1 Capsid Inhibitor GS-6207 Presented at CROI 2020
Mar 10, 2020 02:34PM Gilead (GILD) Announces Treatment With its Vesatolimod is Evaluated for Safety and Virologic and Immunologic Response Versus Placebo in Phase 1B HIV Functional Cure Study
Mar 10, 2020 02:33PM Treatment With Gilead’s Vesatolimod Is Evaluated for Safety and Virologic and Immunologic Response Versus Placebo in Phase 1B HIV Functional Cure Study
Mar 10, 2020 11:32AM Gilead Sciences (GILD) Presents 96-week DISCOVER Trial Data Demonstrating Favorable Renal and Bone Safety Profile of Descovy® for HIV PrEP in At-Risk Populations
Mar 10, 2020 11:32AM Gilead Presents 96-week DISCOVER Trial Data Demonstrating Favorable Renal and Bone Safety Profile of Descovy® for HIV PrEP in At-Risk Populations
Mar 9, 2020 02:53PM New Data on Gilead’s Biktarvy® Presented at CROI 2020, Including Data in Black Americans and Older Adults
Mar 5, 2020 01:02AM Press release Biocartis Group NV: BIOCARTIS ANNOUNCES 2019 RESULTS AND 2020 OUTLOOK
Mar 2, 2020 09:24AM Pre-Open Stock Movers 03/02: (FTSV) (TRIL) (TWTR) Higher; (BIOC) (ENLV) (NVAX) Lower (more...)
Feb 26, 2020 05:00PM Gilead Sciences (GILD) Initiates Two Phase 3 Studies of Remdesivir for Treatment of COVID-19
Feb 26, 2020 05:00PM Gilead Sciences Initiates Two Phase 3 Studies of Investigational Antiviral Remdesivir for the Treatment of COVID-19
View More Recent Stories View Older Stories